This is my TAKHZYRO EXPERIENCE

IMAGINE yours

Join the 3,250+ people since 2018* who have chosen to help prevent hereditary angioedema (HAE) attacks before they happen.

CLICK TO GET STARTED

*Based on third-party US specialty pharmacy data.

WHAT IS TAKHZYRO?

TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 2 years of age and older.

It is not known if TAKHZYRO is safe and effective in children under 2 years of age.

IMPORTANT SAFETY INFORMATION

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

- wheezing
- difficulty breathing
- chest tightness
- fast heartbeat
- faintness
- rash
- hives

Please see additional Important Safety Information throughout and full Prescribing Information, including information for patients.

TAKHZYRO®
(lanadelumab-flyo) injection

HOW IS HAE IMPACTING YOUR LIFE?

No two people experience HAE attacks the same way.

Attacks may be:

- **Unpredictable**
- **Debilitating**
- **Life-threatening (throat attacks)**

Past attacks do not predict when or where future attacks will occur, including in the airway.

Because HAE can change over time for both children and adults, **the next attack may be nothing like the last.**

The 2020 US Hereditary Angioedema Association (HAEA) guidelines recommend regular review of any HAE management plan—including the consideration of long-term preventive treatment in children and adults.

TAKHZYRO is the #1 prescribed HAE preventive treatment*

Prescribed by doctors for over 4 years, TAKHZYRO is recommended by the US HAEA guidelines as one of the first-line treatments for long-term prevention of HAE attacks in people 12 years of age and older.

[*Based on total patients on HAE preventive treatments according to US third-party industry healthcare data.]

IMPORTANT SAFETY INFORMATION (cont'd)

The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, headache, rash, dizziness, diarrhea, and muscle aches.

These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to FDA at 1-800-FDA-1088.



Individuals featured are TAKHZYRO patients as of 2023 and are sharing their own experiences. Individual experiences may vary.

Do more than treat HAE attacks when they happen. Prevention is possible. **Ask your doctor if TAKHZYRO is the right preventive treatment option for you.**

Please see additional Important Safety Information throughout and full Prescribing Information, including information for patients.

TAKHZYRO® (lanadelumab-flyo) injection

FREEDOM FROM HAE ATTACKS FOR UP TO A YEAR FOR SOME PEOPLE

First study leading to FDA approval of TAKHZYRO:

The 6.5-month clinical study included 125 people diagnosed with **HAE aged 12 years and older**. The main goal of the study was to evaluate the ability of TAKHZYRO 300 mg every 2 weeks to reduce the frequency of HAE attacks.

On average, people had

87%
FEWER ATTACKS
compared with placebo

of people
HAD ZERO ATTACKS
for the entire 6.5-month study
compared with 2% of those taking placebo

All data presented are for TAKHZYRO 300 mg every 2 weeks unless otherwise indicated.

IMPORTANT SAFETY INFORMATION (cont'd)

TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

Second study completed after FDA approval:

The 2.5-year, open-label extension clinical study included 212 people diagnosed with **HAE aged 12 years and older**. The main goal of this study was to evaluate the long-term safety of TAKHZYRO 300 mg every 2 weeks. Patients knew they were receiving TAKHZYRO, which could have influenced the study results.

On average, people had

87%
FEWER ATTACKS
compared with baseline

of people
HAD ZERO ATTACKS
for up to a year

In this study, people taking TAKHZYRO for an average of 2.5 years **had similar results to those in the 6.5-month clinical study**.

Please see additional Important Safety Information throughout and full Prescribing Information, including information for patients.

TAKHZYRO®
(lanadelumab-flyo) injection

SAFETY RESULTS ESTABLISHED IN ONE OF THE LARGEST PREVENTION STUDIES IN HAE

TAKHZYRO may cause serious side effects, including allergic reactions.

Call your healthcare provider or get emergency help right away if you have symptoms of an allergic reaction.

Injection site reactions were the most common side effects of TAKHZYRO in the clinical study with people aged 12 years and older.

Most common side effects in the 6.5-month clinical study	TAKHZYRO (84 people)*	Placebo (41 people)
Injection site reactions	52%	34%
○ Pain	43%	29%
○ Redness	10%	2%
○ Bruising	7%	0%
Upper respiratory infection	29%	32%
Headache	21%	22%
Rash	7%	5%
Dizziness	6%	0%
Diarrhea	5%	5%
Muscle aches	5%	0%

The table above shows side effects that occurred in ≥10% of people taking TAKHZYRO.

*Included all people treated with TAKHZYRO (300 mg every 2 weeks, 300 mg every 4 weeks, or 150 mg every 4 weeks) in the first study.

You may report side effects to FDA at 1-800-FDA-1088.

The most common side effects seen in the long-term, open-label study included injection site reactions (pain, redness, and bruising), upper respiratory infections, and headache.

Most common side effects in the 2.5-year, open-label study	TAKHZYRO 300 mg every 2 weeks (212 people)
Injection site pain	47%
Viral upper respiratory tract infection	42%
Upper respiratory tract infection	26%
Headache	25%
Injection site redness	17%
Joint pain	13%
Injection site bruising	12%
Back pain	12%
Diarrhea	11%
Sinus infection	11%
Influenza	10%
Nausea	10%
Urinary tract infection	10%

Please see additional Important Safety Information throughout and full Prescribing Information, including information for patients.

TAKHZYRO®
(lanadelumab-flyo) injection

FREEDOM FROM DAILY DOSING

≤1
MINUTE TO SELF-INJECT
for most people in the clinical studies*

2
WEEKS BETWEEN EACH DOSE
for patients 12 years of age and older

3
CHOICES FOR INJECTION SITE
stomach, thigh, or upper arm

TAKHZYRO is a plasma-free, subcutaneous (under-the-skin) injection that you give yourself.

The recommended starting dosage for people 12 years of age and older is 300 mg every 2 weeks. **It takes about 6 doses of TAKHZYRO for the amount of medication to become constant in your body.** If you experience zero attacks for more than 6 months, your doctor may consider prescribing TAKHZYRO 300 mg every 4 weeks.

Before starting treatment with TAKHZYRO, you will receive training to ensure you know how to administer your therapy. **Do not attempt to take TAKHZYRO without first being trained by a healthcare provider.**

Learn about how TAKHZYRO works, and more, at **TAKHZYRO.com**.

*Most people 12 years of age and older taking TAKHZYRO were able to self-inject in 10 to 60 seconds. These injection times are based on vial administration.

IMPORTANT SAFETY INFORMATION

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

- wheezing
- difficulty breathing
- chest tightness
- fast heartbeat
- faintness
- rash
- hives

Please see additional Important Safety Information throughout and full Prescribing Information, including information for patients.

TAKHZYRO®
(lanadelumab-flyo) injection

TAKHZYRO WAS ALSO STUDIED IN CHILDREN

The largest pediatric trial of any preventive treatment in HAE

The 52-week, open-label study included 21 children diagnosed with HAE aged 2 to <12 years. The main goals of the study were to:

Evaluate the safety of TAKHZYRO 150 mg taken once every 2 weeks or every 4 weeks

Measure levels of TAKHZYRO in the body for children 2 to <12 years of age

In the 52-week study, there were:

- No serious side effects reported
- No discontinuations due to side effects
- No allergic reactions related to TAKHZYRO

In addition, levels of TAKHZYRO in the body for children 2 to <12 years of age who received 150 mg every 2 or 4 weeks were similar to those in adult patients receiving TAKHZYRO 300 mg every 2 weeks.

Most common related TEAEs in children taking TAKHZYRO 150 mg every 2 or 4 weeks (21 children)

- Injection site pain: **29%**
- Injection site redness: **14%**
- Injection site swelling: **5%**
- Administration site pain: **5%**
- Injection site reaction: **5%**

TEAE=treatment-emergent adverse event.

IMPORTANT SAFETY INFORMATION (cont'd)

TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

Please see additional Important Safety Information throughout and full Prescribing Information, including information for patients.

TAKHZYRO® (lanadelumab-flyo) injection

THE EFFECTIVENESS OF TAKHZYRO IN CHILDREN

Use of TAKHZYRO in children 2 to <12 years of age was supported by:

- Efficacy data from the 6.5-month study in people 12 years of age and older
- Additional data that showed similar levels of TAKHZYRO were reached in the body for adults and children

A secondary goal of the 52-week study was to measure the ability of TAKHZYRO 150 mg taken once every 2 weeks or every 4 weeks to prevent HAE attacks in 21 children 2 to <12 years of age. Decrease in HAE attacks was measured as the number of attacks before the patient started in the study compared to the number of HAE attacks after taking TAKHZYRO.

An important note about this study

The study was not designed to understand how well TAKHZYRO works in children. The 21 children included knew they were taking TAKHZYRO. This study did not compare TAKHZYRO to another product or placebo. These details make it difficult to determine how well TAKHZYRO decreased HAE attacks in children.

On average, children had:

- **95%** fewer HAE attacks compared to before starting the study
- **76%** of children were attack free for the entire 52-week study

DOSING THAT FITS IN YOUR CHILD'S LIFE

Recommended dosages

For children 2 to 5 years of age, 150 mg every

4 WEEKS

For children 6 to 11 years of age, 150 mg every

2 WEEKS

If your child is taking TAKHZYRO every 2 weeks and is well controlled (for example, experiencing zero HAE attacks for more than 6 months), their doctor may consider switching them to every 4 weeks.

Support from Takeda for you and your child

If you're a parent of a child with HAE, starting TAKHZYRO can be a big step for both of you. Takeda is here with support throughout your journey, beginning with injection training.

Once your child is prescribed TAKHZYRO, **you will receive training to ensure you know how to administer their therapy**.

Self-administration is not recommended in children 2 to <12 years of age.

IMPORTANT SAFETY INFORMATION

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

- wheezing
- difficulty breathing
- chest tightness
- fast heartbeat
- faintness
- rash
- hives

Please see additional Important Safety Information throughout and full Prescribing Information, including information for patients.

TAKHZYRO® (lanadelumab-flyo) injection

OnePath® IS HERE TO HELP

OnePath is a free product support program for eligible patients who have been prescribed a Takeda product. If you have any questions or need assistance, do not hesitate to reach out. OnePath is available at **1-866-888-0660**, Monday through Friday, 8:30 AM to 8:00 PM ET.

Here are just a few ways that OnePath can help:

A dedicated Patient Support Manager

A single point of contact who is ready to assist you with product support needs

Financial assistance options

Co-pay assistance for those who are eligible,* as well as assistance with navigating insurance coverage

Injection training

In-home training from a specially trained nurse for you or a caregiver on how to administer TAKHZYRO® (lanadelumab-flyo)

Resources and education

Connecting you and your family members with educational resources, including the free OnePath Mobile App

*At a minimum to be eligible, patients must have commercial insurance. Other terms and conditions apply. Contact OnePath for more information.

Washanda
Caregiver supported by OnePath

Please see Important Safety Information throughout and full Prescribing Information, including information for patients.

IMAGINE YOUR TAKHZYRO EXPERIENCE

- HAE attacks can be unpredictable, debilitating, and potentially life-threatening
- In a **6.5-month clinical study**, people 12 years of age and older taking TAKHZYRO 300 mg every 2 weeks experienced **87% FEWER ATTACKS** on average compared with placebo
- Freedom from daily dosing: for people 12 years of age and older, self-administer 1 dose in a minute or less every 2 weeks*

Visit **TAKHZYRO.com/reviews** to hear real patients talk about their experience.

*Most people 12 years of age and older taking TAKHZYRO were able to self-inject in 10 to 60 seconds. These injection times are based on vial administration.

WHAT IS TAKHZYRO?

TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 2 years of age and older.

It is not known if TAKHZYRO is safe and effective in children under 2 years of age.

IMPORTANT SAFETY INFORMATION

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

- wheezing
- difficulty breathing
- chest tightness
- fast heartbeat
- faintness
- rash
- hives

Please see additional Important Safety Information throughout and full Prescribing Information, including information for patients.

Takeda

US-LANA-1481v1.0 03/23

Visit us on:

TAKHZYRO®
(lanadelumab-flyo) injection